DGCI cancels licenses of 18 pharma companies

In a series of stringent actions being taken against spurious medications making substandard drugs following the incidents reports in Gambia and Uzbekistan, official sources from the government have claimed that the Drug Controller General of India (DCGI), the country’s drug regulator, has cracked the whip on 76 firms and cancelled product permissions of three firms. A joint team of central government and state government took a surprise check on these firms.

Under the drive, the licences of 18 firms have either been cancelled or suspended. Sources have claimed that the latest action might be led to the closure of some Pharmaceutical companies found making spurious or contaminated drugs. These 76 firms are spread across 20 states and under phase 1 of the drive, 26 firms have also received show-cause notices.

The 20 states inspected by officials include Andhra Pradesh, Bihar, Goa, Gujarat, Bihar, Delhi, Haryana, Himachal Pradesh, Jammu and Kashmir, Karnataka, Madhya Pradesh, Maharashtra, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Telangana, Uttar Pradesh, Uttarakhand and West Bengal. CNBCTV18